Background: Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that recently gained Food and Drug Administration approval for late-line metastatic breast cancer (MBC). [95% confidence interval (CI) 12.9-31.8; all partial responses (PRs)], stable disease (SD) occurred in 30 patients (37.5%) and the clinical benefit rate (complete response + PR + SD ‡6 months) was 27.5% (95% CI 18.1-38.6). Median duration of response was 3.9 months (95% CI 2.8-4.9), progression-free survival was 3.7 months (95% CI 2.0-4.4) and overall survival was 11.1 months (95% CI 7.9-15.8). The most frequent treatment-related grade 3/4 adverse events were neutropenia (95.1%), leukopenia (74.1%) and febrile neutropenia (13.6%). Grade 3 peripheral neuropathy occurred in 3.7% of patients (no grade 4).
introduction
Patients with advanced or metastatic breast cancer (MBC) have very few effective treatment options, and the lack of successful disease management strategies is reflected by a 5-year survival rate of only 23% [1] . Anthracyclines and taxanes are the standard chemotherapeutics employed for MBC, but many patients fail to respond or become refractory to these agents [2] [3] [4] . Monotherapies approved for use in the late-line setting include capecitabine, gemcitabine and vinorelbine, to which drug resistance may also be acquired. Ixabepilone represents one alternative treatment option which has been approved for the treatment of patients with taxane-, anthracycline-and capecitabine-resistant MBC [5] . There continues to be a significant unmet need for additional treatment options that are effective, well tolerated and easily administered for women with MBC who have been heavily pretreated with conventional chemotherapeutic agents.
Recently, eribulin mesylate (Halavenä; E7389) has received approval in the United States, the European Union and Singapore for the treatment of patients with MBC who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin is also approved in Japan for the treatment of patients with inoperable or recurrent breast cancer, who have received prior chemotherapy including an anthracycline and a taxane and have progressed or relapsed since their last chemotherapeutic regimen.
Eribulin is a non-taxane microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. With a mechanism of action distinct from currently available tubulin-targeting compounds, eribulin inhibits microtubule polymerisation without affecting depolymerisation and induces the formation of non-productive tubulin aggregates [6] [7] [8] [9] [10] . In preclinical studies, eribulin retained activity in ovarian cancer cell lines that were resistant to paclitaxel due to b-tubulin mutations [11] .
Eribulin has demonstrated efficacy in phase I dose-finding studies [12] [13] [14] and in phase II studies involving patients with heavily pretreated MBC who had previously received an anthracycline and a taxane [15] or an anthracycline and a taxane plus capecitabine [16] . Based on these studies, an additional phase I dose-finding study investigated eribulin mesylate i.v. infusion for 2-10 min on days 1 and 8 of a 21-day cycle in Japanese patients. This study established a recommended dose of 1.4 mg/m 2 for subsequent phase II trials in Japanese patients [17] . The phase II study reported here is the first to investigate the efficacy and safety of eribulin in Japanese patients with heavily pretreated locally advanced or MBC.
methods study design
This phase II, open-label single-arm multicentre study (Study E7389-J081-221, NCT00633100) was conducted at 22 sites in Japan and recruited patients with locally advanced breast cancer or MBC who had previously been treated with an anthracycline and a taxane. The primary objective of this study was to investigate the objective response rate (ORR) and safety of eribulin. Secondary objectives were to evaluate the duration of response (DOR), progression-free survival (PFS) and overall survival (OS) attributed to eribulin treatment.
The study was conducted in accordance with the Declaration of Helsinki revised edition (World Medical Association General Assembly, Tokyo, 2004), article 80-2 of the Japanese Pharmaceutical Affairs Law and Good Clinical Practice for Trials of Drugs. The protocol was approved by local institutional review boards and ethics committees and patients provided written informed consent.
patients
Key inclusion criteria were: women aged between ‡20 and <75 years with histologically or cytologically confirmed breast cancer with evaluable disease; previous treatment with £3 chemotherapeutic regimens in the metastatic setting, including an anthracycline and a taxane; relapse during or within a year after neoadjuvant or post-operative adjuvant chemotherapy immediately before the study, or progression during or within 6 months of last chemotherapy in the metastatic setting; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; measurable lesion in at least one dimension by computed tomography or magnetic resonance imaging; neutrophil count ‡1500/ll, platelet count ‡100 000/ll and haemoglobin ‡9.0 g/dl; aspartate aminotransferase and alanine aminotransferase £2.5 times the upper limit of normal (ULN) or £5.0 · ULN in patients with hepatic metastases; total bilirubin £1.5 · ULN; serum creatinine £1.5 · ULN; expected survival of ‡3 months and no effect or adverse drug reactions with prior therapy that would affect the safety evaluation of eribulin treatment, excluding alopecia and grade 1 neuropathy. Key exclusion criteria were: systemic infection with fever; pleural effusion, ascites or pericardial fluid requiring drainage; brain metastasis with clinical symptoms; serious complications (including ischaemic heart disease not controllable by treatment or heart disease such as arrhythmia; myocardial infarction <6 months prior to study entry; complication of hepatic cirrhosis; interstitial pneumonia or pulmonary fibrosis and bleeding tendency); active double cancer; pregnancy, breast-feeding or women with childbearing potential who do not agree to use appropriate contraception; requirement of continuous steroid systematic treatment or use of drugs that modulate CYP3A4 activity; previous extensive radiotherapy ( ‡30% of bone marrow) and refusal of blood transfusion for supportive therapy. in the event of grade 3 or more neutropenia, grade 3 or more thrombocytopaenia or at investigators' discretion. A new treatment cycle could be postponed for a maximum of 2 weeks in the event of <1500/ll neutrophil count or <100 000/ll platelet count or at investigators' discretion. Patients requiring dose delay >2 weeks were discontinued. Dose interruption occurred when i.v. administration was interrupted during the infusion period.
Concomitant therapy that did not interfere with the evaluation of eribulin was permitted at the investigators' discretion excluding other anticancer therapies. Granulocyte colony-stimulating factor (G-CSF) was permitted in the event of grade 4 neutropenia, grade 3 or more febrile neutropenia or when grade 3 or more neutropenia was observed in subsequent treatment cycles in patients who had experienced either of the aforementioned adverse events (AEs) in a previous cycle. assessments Independent blinded review was performed for all tumour assessments except for those in patients who experienced progression by investigator assessment before or at the end of treatment cycle 2. The primary end point analysis, including ORR, was based upon radiographic assessments by independent review. Tumour responses of target lesions were evaluated according to Response Evaluation Criteria in Solid Tumours [18] at screening (within 28 days of the start of eribulin administration) and then every 6 weeks (62 weeks). Responses were classified as follows: complete response (CR); partial response (PR); progressive disease (PD); stable disease (SD) and not evaluable (NE). CR or PR required confirmation by a second assessment 4 weeks later. ORR was defined as CR + PR; clinical benefit rate (CBR) was defined as CR + PR + SD ‡6 months' duration. DOR was measured from first documented CR or PR to the earliest date of objective PD, death or censoring. PFS was assessed from date of enrolment to the earliest date of objective PD, death or censoring. OS was assessed from date of enrolment to the date of death or censoring. Subgroup analyses were stratified by parameters including receptor status 
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and the number of prior chemotherapy regimens for advanced or MBC. AEs were recorded and graded according to the National Cancer Institute Common Terminology Criteria for AEs Version 3.0, Japanese version, and were coded according to Medical Dictionary for Regulatory Activities, Japanese version.
statistical methods
ORR and two-sided 95% confidence intervals (CIs) were calculated based on binominal distribution. DOR, PFS and OS (range and median with 95% CI) were calculated using Kaplan-Meier estimates. Safety data were evaluated using descriptive statistics.
Efficacy end points were assessed in the eligible population [full analysis set (FAS)] of patients with histologically or cytologically confirmed breast cancer who received at least one eribulin dose for study treatment and had evaluable efficacy data. The safety population included all patients who received at least one eribulin dose.
The estimated total sample size of 78-82 was determined based on the two-stage design by Bayesian and frequentist approaches. Using ORR as the primary efficacy end point, the threshold ORR (P 0 ) was determined to be 10% and the expected ORR (P 1 ) was 20%. Early stopping rule of two or less than two objective responses in the first stage (26-28 patients) was constructed by a ‡90% and a ‡50% of Bayesian posterior probability for the true ORR < P 1 and < P 0 , respectively. With an overall 5% type-I error rate and a 20% rype-II error rate (power 80%) at the specified P 0 and P 1 , if objective response is confirmed in ‡13 patients out of 78-82 patients, eribulin was to be considered active and P 0 was to be rejected.
results patients
In total, 84 patients were recruited to this study between January 2008 and September 2009. The safety population comprised 81 patients who received eribulin, and 80 patients were included in the eligible (FAS) population (Figure 1 ). Within the eligible population, patients had received a median of three prior chemotherapy regimens (range 1-5); 57.5% and 11.3% had received prior capecitabine and tegafur/gimeracil/ oteracil potassium, respectively; 65.0% were hormone receptor [oestrogen receptor (ER) and/or progesterone receptor (PgR)]-positive; 11.3% were human epidermal growth factor receptor 2 (HER2/neu)-positive and 27.5% were triple-negative (HER2/ neu, ER, PgR) ( Table 1 ). All patients had MBC, and the most common metastatic sites were lymph nodes (67.5%), bone (63.8%), liver (61.3%) and lung (47.5%). 
efficacy
Eribulin demonstrated an ORR of 21.3% (95% CI 12.9-31.8) in the eligible population by independent review, consisting of all PRs, and the CBR was 27.5% (95% CI 18.1-38.6) ( Table 2 ). The maximum change in tumour size (sum of the longest single dimension for measurable lesions) in each patient is shown in Figure 2A . Median DOR was 3.9 months [95% CI 2.8-4.9; range 1.0 Figure 2B ). Independent review of the eligible population determined a median PFS of 3.7 months (95% CI 2.0-4.4; range 0.3-14.8 + ) ( Figure 2C ). The median OS was 11.1 months (95% CI 7.9-15.8; range 1.0-25.9 + ), and 1-year survival was 44.5% (95% CI 33.4-55.0) (eligible population; Figure 2D ). Efficacy end points by investigator review were consistent with those by independent review (data shown for objective tumour response in Table 2 ). Subgroup analysis did not reveal any factor that affected the efficacy of eribulin in this study (Table 3) . Eribulin exhibited efficacy at metastatic sites, demonstrated by tumour shrinkage in the liver, lymph nodes and lung (Figure 3) . The most common AEs with eribulin were neutropenia (98.8%), leukopenia (98.8%), alopecia (58.0%) and lymphopenia (54.3%), and the most common grade 3/4 AEs were neutropenia (95.1%) and leukopenia (74.1%) ( Table 4) . Febrile neutropenia occurred in 11 patients (13.6%) and G-CSF was administered in 21 patients (25.9%) for symptomatic neutropenia treatment. A low incidence of peripheral sensory neuropathy was observed, with 3.7% of patients reporting a severity of grade 3 (no grade 4), and an overall incidence of 23.5%. Although patient numbers were small, the incidence of grade 2 or 3 neuropathy was similar for patients with preexisting grade 1 neuropathy [of 32 patients, 3 (9.4%) and 2 (6.3%) reported grade 2 and grade 3, respectively] to those without the condition at baseline [of 49 patients, 3 (6.1%) and 1 (2.0%) reported grade 2 and grade 3, respectively]. Six patients (7.4%) discontinued drug administration due to AEs of neutropenia, stomatitis, fatigue, alanine aminotransferase increased, decreased appetite, cancer pain, dysgeusia, peripheral sensory neuropathy and interstitial lung disease, none of which was observed in more than one patient. There was one death during the study of acute aggravation/ progression of the primary disease, which accompanied an infection assumed to be caused by malaise with a reduced ability for self-care and neutropenia. The causal relationship of the infection to eribulin could not be ruled out. Serious AEs other than death occurred in 13 patients (16.0%), for which causal relationship to eribulin could not be ruled out in 8 (9.9%) patients.
discussion
In this first phase II study of eribulin in Japanese patients with locally advanced disease or MBC previously treated with an anthracycline and a taxane, eribulin demonstrated antitumour activity with an ORR of 21.3% by independent review and a manageable tolerability profile. Secondary efficacy end points were broadly consistent with ORR results, with a CBR of 27.5%, and median DOR, PFS and OS of 3.9, 3.7 and 11.1 months, respectively. Efficacy results were consistent across patient subgroups, but subgroup sizes were generally too small to assess effects, and the CIs were often wide and overlapping. Analysis of tumour shrinkage in lymph node, liver and lung metastases suggests that eribulin was active at visceral and non-visceral metastatic sites. A previous phase II study of eribulin mesylate that reported activity of 1.4 mg/m 2 using the identical dosing schedule in extensively pretreated patients in both the USA and European Union [16] . In this study, the ORR was 9.3% (95% CI 6.1-13.4), the CBR was 17.1% (95% CI 12.8-22.1) and median DOR was established as 4.1 months. These results demonstrate activity of eribulin across the geographical regions investigated. Differences in efficacy rates between these two studies may be explained by differences in the type and number of prior chemotherapy regimens received or ECOG performance status at baseline. Patients recruited to our study had previously received an anthracycline or a taxane, with a median of 3 (range 1-5) prior chemotherapy regimens, and 72.5% of patients had a baseline ECOG score of 0. In the previous study, in which all patients had previously received capecitabine, an anthracycline and a taxane, the median number of prior chemotherapy regimens was 4 (range 1-6) and 37.2% of patients exhibited a baseline ECOG score of 0 [16] . In addition, the number of treatment modifications throughout each study may differ, which may also contribute to the observed differences in efficacy rates.
The overall tolerability profile demonstrated by eribulin in this study is in line with safety profiles reported in previous phase I and II trials [12] [13] [14] [15] [16] . Haematological events such as neutropenia and leukopenia have similarly been the most commonly reported grade 3/4 AEs in this and other phase II studies. However, the incidences of febrile neutropenia were higher in our study, occurring in 11 (13.6%) patients compared with 5.5% and 4.0% in previous phase II trials [15, 16] . Notably, in this trial, only 3.7% of patients experienced grade 3 peripheral sensory neuropathy and no grade 4 incidences of this AE occurred. This is also comparable to findings reported in the two previous phase II studies, in which grade 3 incidences occurred in only 6.9% and 5.0% of patients, respectively, and no grade 4 events were noted in either study [15, 16] . These results suggest a minimal contribution of eribulin towards the potentiation of peripheral neuropathic symptoms. As this often debilitating condition is associated with exposure to chemotherapies such as taxanes and epothilones, avoiding induction or further aggravation of neuropathy is a priority for the appropriate selection of late-line treatments for patients with MBC [19] . Further important considerations in this setting are Cremophor sensitivity and the ease of chemotherapy administration. In this regard, eribulin has a rapid infusion time and no requirement for pre-medication to manage Cremophor hypersensitivity.
Genetic polymorphisms may affect chemotherapeutic response in different patient populations [20] . Recent studies suggest that P-glycoprotein (P-gp) may be involved in eribulin disposition [21] and that a polymorphism of MDR1, the gene encoding P-gp, affects chemotherapeutic outcome [22] . Further investigation is needed to evaluate whether pharmacogenetic variation contributes to eribulin efficacy and safety.
Despite the prevalence of chemotherapeutic resistance among patients with breast cancer, this study is one of the few phase II trials that have focused upon Japanese patients who have relapsed or progressed following anthracycline and taxane treatment. A recent phase II trial in this particular patient group evaluated gemcitabine monotherapy, administered on days 1 and 8 of a 21-day cycle and reported an ORR of 8.1% (95% CI 2.7-17.8) and a median time to progression of 92 days (range 29-651) [23] . A study of vinorelbine in this same setting with an identical dosing schedule determined an ORR of 20.0% (95% CI 10.0-33.7), with a median time to progression of 115 days [24] . Other phase II trials in anthracycline-and taxane-resistant Japanese patients have investigated activity of the HER2-targeting agents lapatinib or trastuzumab (in combination with capecitabine) [25, 26] . These studies reported an ORR of 19.0% (95% CI 11.8-28.1) and 18.4% (95% CI 7.7-34.3), respectively, in HER2-positive patients [25, 26] . To date, no randomised phase III studies for anthracycline-and taxaneresistant Japanese patients have been reported. However, results of a large global phase III study of eribulin compared with treatment of physicians' choice have recently been reported and have demonstrated a statistically significant increase in median OS of 2.5 months (23%) with eribulin [27] . A further phase III trial comparing eribulin efficacy with capecitabine (NCT00337103) in patients with locally advanced disease or MBC who had received up to three prior chemotherapy regimens is ongoing, and results are awaited with interest [28] .
In conclusion, in this phase II study involving Japanese patients with locally advanced disease or MBC previously treated with an anthracycline and a taxane, eribulin showed antitumour activity and had a manageable tolerability profile that is consistent with previous phase II studies. These results, together with data from the recently published phase III trial, support the use of eribulin in this setting and further evaluation is warranted. 
